Hybrid antibodies can target sites for attack by T cells
- PMID: 2859527
- DOI: 10.1038/314628a0
Hybrid antibodies can target sites for attack by T cells
Abstract
It would be advantageous in the case of certain diseases to be able to focus a strong T-cell response at a chosen target, for example, in treating cancer or infections that have escaped the normal host response. At present, it seems inconceivable that we could use antigen-specific lines or clones of effector T cells for this purpose because of complications due to the major histocompatibility restriction of T-cell specificity and the problem of rejection of transplanted effector cells. Here we describe a novel technology which combines the power of T lymphocytes in eliminating unwanted cells and causing beneficial inflammatory reactions with the great advantages of monoclonal antibodies (their specificity and availability). We show that heteroconjugates of monoclonal antibodies (referred to hereafter as hybrid antibodies), in which one of the component binding sites is anti-T-cell receptor and the other component binding site is directed against any chosen target antigen, can focus T cells to act at the targeted site. Monoclonal antibodies directed against the T-cell receptor, such as the anti-allotype used here, are mitogenic for resting T cells and can be used to induce effector T cells carrying the T-cell receptor determinant which can then be directed against the target by a hybrid antibody.
Similar articles
-
Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity.Proc Natl Acad Sci U S A. 1986 Mar;83(5):1453-7. doi: 10.1073/pnas.83.5.1453. Proc Natl Acad Sci U S A. 1986. PMID: 2869486 Free PMC article.
-
Redirecting the cellular immune response.Int Rev Immunol. 1989 May;4(2):159-73. doi: 10.3109/08830188909044779. Int Rev Immunol. 1989. PMID: 2485840 Review.
-
Characteristics of a monoclonal antibody (WT-31) that recognizes a common epitope on the human T cell receptor for antigen.J Immunol. 1985 Sep;135(3):1922-8. J Immunol. 1985. PMID: 2410507
-
Effective activation of resting mouse T lymphocytes by cross-linking submitogenic concentrations of the T cell antigen receptor with either Lyt-2 or L3T4.Eur J Immunol. 1987 May;17(5):643-50. doi: 10.1002/eji.1830170510. Eur J Immunol. 1987. PMID: 3108015
-
Targeting of T or NK lymphocytes against tumor cells by bispecific monoclonal antibodies: role of different triggering molecules.Int J Cancer Suppl. 1992;7:15-8. Int J Cancer Suppl. 1992. PMID: 1428398 Review.
Cited by
-
Bispecific antibodies: a novel approach for targeting prominent biomarkers.Hum Vaccin Immunother. 2020 Nov 1;16(11):2831-2839. doi: 10.1080/21645515.2020.1738167. Epub 2020 Jul 2. Hum Vaccin Immunother. 2020. PMID: 32614706 Free PMC article.
-
Self-assembled antibody multimers through peptide nucleic acid conjugation.J Am Chem Soc. 2013 Jan 9;135(1):340-6. doi: 10.1021/ja309505c. Epub 2012 Dec 21. J Am Chem Soc. 2013. PMID: 23210862 Free PMC article.
-
Characterization of a bispecific FLT3 X CD3 antibody in an improved, recombinant format for the treatment of leukemia.Mol Ther. 2015 Apr;23(4):648-55. doi: 10.1038/mt.2015.2. Epub 2015 Jan 12. Mol Ther. 2015. PMID: 25578618 Free PMC article.
-
Introduction to monoclonal antibodies.Cancer Immun. 2012;12:11. Epub 2012 May 1. Cancer Immun. 2012. PMID: 22896756 Free PMC article. Review. No abstract available.
-
Triggering T cells by otherwise inert hybrid anti-CD3/antitumor antibodies requires encounter with the specific target cell.J Exp Med. 1989 Jul 1;170(1):297-302. doi: 10.1084/jem.170.1.297. J Exp Med. 1989. PMID: 2526194 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources